The short version of GIP receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-10 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
The Phoenicians also made a deep blue-coloured dye, sometimes referred to as royal blue or hyacinth purple, which was made from a closely related species of marine snail. The Phoenicians established an ancillary production facility on the Iles Purpuraires at Mogador, in Morocco. The sea snail harvested at this western Moroccan dye production facility was Hexaplex trunculus, also known by the older name Murex trunculus. This second species of dye murex is found today on the Mediterranean and Atlantic coasts of Europe and Africa (Spain, Portugal, Morocco).
Trans fats occur in meat and dairy products from ruminants. For example, butter contains about 3% trans fat by weight. These naturally occurring trans fats include conjugated linoleic acid (CLA) and vaccenic acid (trans-11 18:1). They arise from the action of bacteria in the rumen. Polyunsaturated fats are toxic to the rumen-based bacteria, which detoxify the fats by changing some cis-double bonds to trans-double bonds. In contrast to industrially produced trans fats, this bacterial process produces only a few specific isomers. Conjugated trans fatty acids such as CLA are exempt from counting as trans fat in the US. The Codex Alimentarius includes an analogous exclusion. As industrial sources of trans fats are eliminated, increased attention focuses on ruminant derived trans fats. Not all ruminant-derived trans fats are innocuous like vaccenic acid and its metabolite rumenic acid (cis-9-trans-11 CLA / 18:2). In particular, trans-10 18:1 is not turned into a conjugated linoleic acid by humans. It appears to have health consequences comparable to trans fats of industrial origin.
=== 23 July === General Al-Taj Youssef Aboukadair, a senior RSF commander also known as Folgank, was killed by an SAF drone strike in Abu Zabad that also killed two other RSF commanders. At least 32 people were killed in an RSF attack on the village of Brima Rashid in West Kordofan.
An alginate dressing is a natural wound dressing derived from carbohydrate sources released by clinical bacterial species, in the same manner as biofilm formation. These types of dressings are best used on wounds that have a large amount of exudate. They may be used on full-thickness burns, surgical wounds, split-thickness graft donor sites, Mohs surgery defects, refractory decubiti, and chronic ulcers. They can also be applied onto dry wounds after normal saline is first applied to the site of application. Alginate dressings are produced from the calcium and sodium salts of alginic acid, a polysaccharide comprising mannuronic and guluronic acid units. Alginate is initially extracted from the cell wall of brown seaweeds. Alginate dressings can be in the form of freeze-dried, porous (foam) sheets or flexible fibres. Flexible fibres are used to treat cavity wounds. The alginate will form a gel in contact with the exudates of the wound and give it a strong absorbent power.
Sources: en.wikipedia.org
=== Other research === As of July 2013, afamelanotide was in phase II and III clinical trials for vitiligo and other skin diseases. A medication for rheumatoid arthritis, tofacitinib, has been tested for the treatment of vitiligo. According to a 2021 review, JAK inhibitors like ruxolitinib show promise in targeting the IFN-γ-chemokine signaling axis implicated in vitiligo pathogenesis and improving NSV. In mid-2026, pharmaceutical corporation Pfizer announced positive phase III trial results of ritlecitinib, a kinas-inhibiting drug, to treat NSV. Additionally, a 2026 study published in The Lancet showed positive results with the JAK inhibitor upadacitinib. As of 2024, mitochondrial antioxidants, NRF2 inhibitors, and TBK1 inhibitors were emerging as potential therapeutic options to block the effects of melanocytic mtDNA release associated with vitiligo. The head of a 2025 Osaka Metropolitan University research team suggested that its discoveries, which included the presence of dormant pigment cells in vitiligo patches, could lead to new treatment approaches.
== Signs and symptoms == The characteristic symptom is numbness, tingling, or burning sensations in the thumb, index, middle, and radial half of the ring finger. These areas process sensation through the median nerve. Numbness or tingling is usually worse with sleep. People tend to sleep with their wrists flexed, which increases pressure on the nerve. Ache and discomfort may be reported in the forearm or even the upper arm. Symptoms that are not as characteristic of CTS include pain in the wrists or hands, loss of grip strength, minor loss of sleep, and loss of manual dexterity. Severe CTS is associated with measurable loss of sensibility. As the median neuropathy progresses, there is loss of sensibility in the thumb, index, middle, and the thumb side of the ring finger. As the neuropathy progresses, there may be first weakness, then atrophy of the muscles of thenar eminence (the flexor pollicis brevis, opponens pollicis, and abductor pollicis brevis). The sensibility of the palm remains normal because the superficial sensory branch of the median nerve branches proximal to the transverse carpal ligament (TCL) and travels superficial to it. Median nerve symptoms may arise from nerve compression at the level of the thoracic outlet or the area where the median nerve passes between the two heads of the pronator teres in the forearm, although this is debated. Severe CTS is also associated with weakness and atrophy of the muscles at the base of the thumb. The ability to abduct the thumb may be lost.
== L == Larock indole synthesis Lawesson's reagent Lebedev process Lehmstedt–Tanasescu reaction Leimgruber–Batcho indole synthesis Letts nitrile synthesis Leuckart reaction Leuckart thiophenol reaction Leuckart–Wallach reaction Leuckart amide synthesis Levinstein process Ley–Griffith oxidation, Ley oxidation Lieben iodoform reaction, Haloform reaction Liebeskind–Srogl coupling Liebig melamine synthesis Lindlar catalyst Lobry de Bruyn–Van Ekenstein transformation Lombardo methylenation Lossen rearrangement Lucas' reagent Luche reduction
Sources: en.wikipedia.org
Though 5-HTP is found in food only in insignificant quantities, it is a chemical involved intermediately in the metabolism of tryptophan, an amino acid found in all unfractionated foods, with lower total amino acid content correlating with increased tryptophan absorption.
The difference between the 1971 model and the eventual Il-86 was in configuration: the model had looked like an Il-62. At that time, the Central Aero and Hydrodynamics Institute (TsAGI) favoured the clean-winged, rear-engined, T-tailed configuration for airliners. The BAC Three-Eleven and BAC/CASA/MBB Europlane projects had similar configurations. The configuration of heavy jet aircraft was a politically sensitive issue in the USSR. Aircraft designer Leonid Selyakov states this of the underwing-engine US-pioneered layout which gradually became standard for jet airliners: "The configuration of the В-47, taken on strength by the US Air Force ... brought forth a veritable storm of critical opinions from [Soviet] aviation scientists. Responsible TsAGI officials and industry leaders robustly called that aircraft 'utter nonsense' (similar opinions were expressed of the Boeing 747)." Similar controversies were known in Western aeronautical circles but this Soviet approach showed a typical streak of dogmatism which held that problems had immutable, "scientifically correct" solutions. However, not all Soviet aviation engineers were so fixed in their ideas, and the configuration issue figured in a meeting held discreetly in Paris in the late 1960s between Boeing engineers (including Joe Sutter, chief project engineer for the 747, and Bob Withington, a senior engineer who was deeply involved in the SST program) and some of their Soviet counterparts.
Little People of the World Organization Archived 2021-05-10 at the Wayback Machine [Hub for all International Organizations; services/advocacy/know your rights/support] Little People of America (Includes a list of International support groups) Little People of Canada (Includes a list of Canadian Provincial support groups) Little People UK Dwarf Sports Association UK Restricted Growth Association UK
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.